Navigation Links
Best Practices in Patient Recruitment and Retention for Diabetes Trials, New Life Science Webinar Hosted by Xtalks
Date:11/8/2013

ks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from pharmaceutical & biotech companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx.

Contact:
Michelle Tran, Marketing Manager
+1 (416) 977-6555 ext 284
mtran(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/11/prweb11309631.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. PAREXEL Introduces Executive Briefing Series on Proven Practices to Assist Emerging and Mid-size Biopharma in Achieving Better Outcomes
2. Innovation Leaders from Across Industries will Convene to Share Best Practices and Breakthrough Successes at Open Innovation Leadership Summit
3. Reno Efficient Sustainable Practices Selected to Provide Water and Energy Conservation Services To the County of San Diego
4. Best Practices, LLC Issues New Report and Webinar on Managing Healthcare Reform through Effective Engagement with the Government Ecosystem
5. First Suit Against Nobel Prize Organization Citing Defamation And Unfair Competition Practices Is Filed
6. How to Ensure Pharmacovigilance Practices are Compliant with Global Safety Requirements: Challenges in Asia-Pacific
7. BioInformatics LLC New Market Report – Best Practices Guide for Advertising to Life Scientists
8. Local Leaders Convene in Boston to Share Industry Best Practices in Second “Business of Big Data” Summit
9. Best Practices for Lean Six Sigma in Clinical Development and R&D, New Xtalks Life Sciences Webinar
10. Alacrita Aggregates the Life Science Practices of Two Consulting Firms and Appoints Simon Turner Ph.D FRSC as Partner
11. Best Practices for Conducting Extractable and Leachable Studies, new life sciences webinar hosted by Xtalks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2015)... RARITAN, N.J. , May 30, 2015 ... single-arm Phase 2 MMY2002 (SIRIUS) trial show treatment ... monoclonal antibody – achieved an overall response rate ... assessed by an independent review committee, in heavily ... consistent among the pre-specified subgroups based on age, ...
(Date:5/29/2015)... Los Gatos, CA (PRWEB) May 29, 2015 ... diagnostics company addressing multi-drug-resistant organisms (MDROs), announced that ... technology for same-shift bacterial detection and susceptibility testing ... asm2015 on May 31, 2015 in ... a new class of molecular diagnostics that can ...
(Date:5/29/2015)... Columbia, Pa. (PRWEB) May 29, 2015 ... Thermal Product Solutions with a request to design ... remove excess moisture from prescription medications being produced ... custom solution that includes a robotic gantry, heat-saving ... positions and dries trays of 3D-printed pills to ...
(Date:5/29/2015)... Results from a Phase III clinical trial examining ... reduce the size of melanoma tumors in patients injected ... of Clinical Oncology. , The global, randomized trial ... melanoma, a potentially fatal form of skin cancer. The ... safety and efficacy of the oncolytic virus immunotherapy compared ...
Breaking Biology Technology:Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3New industrial oven with “pill pushing” robotic gantry precisely removes excess moisture from 3D-printed pharmaceuticals 2Study Published in Journal of Clinical Oncology Reports Talimogene Laherparepvec Improvesdurable Responses in Patients with Advanced Melanoma 2
... ("Phosphagenics") (ASX: POH, AIM: PSG, OTCQX: PPGNY) today,announced ... that showed its,delivery technology, TPM, delivered leading pain-relief ... irritation of any kind., These results support ... a sustained release oxycodone patch for the management ...
... 17 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ; ... a,leading European pharmaceutical and medical devices company, ... Vasogen,s Celacade(TM) System,in Germany. Celacade, a first-in-class ... that specifically targets the destructive chronic,inflammation underlying ...
... SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) today announced ... Board of Directors. Mr. Turner brings over 25 years ... serve on,the company,s audit committee., "We are delighted ... S.,Henney, Chairman of the Board of Directors of SGX. ...
Cached Biology Technology:Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results 2Phosphagenics Announces Successful Phase 1 Transdermal Oxycodone Clinical Trial Results 3Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 2Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 3Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 4Vasogen and Grupo Ferrer Announce Initial Roll-out of Celacade - New Therapy for Chronic Heart Failure 5SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 2SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 3
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, ... the start of a new Phase III double blind, ... its novel formulation, CM-AT, on all children ages 3-8 ... its FDA Phase III double blinded clinical trial for ... low levels of the digestive enzyme chymotrypsin. This new ...
(Date:5/6/2015)... Israel , May 6, 2015 LifeBEAM, ... most established helmet producer, announced today that they will ... Helmet, the world,s first bio-sensing cycling helmet and the ... released in two new colors in order to give ... the product. In addition, LifeBEAM and Lazer announced their ...
(Date:4/27/2015)... 27, 2015 Profile Solutions, Inc. (OTC: PSIQ), ... systems is pleased to announce that Dr Gerry ... and member of its scientific advisory board. ... a thought leader in technology-enhanced learning models. He was ... has published studies and books focused on online student ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4
... is used to soothe every kind of pain, from simple ... is one of the most used nowadays. However, research carried ... University of Granada showed that taking paracetamol slows ... studies. Author of this work is Olga Garca Mart ...
... VIEW, Calif., Aug. 13 LaserCard,Corporation (Nasdaq: ... credentials,used in biometric identification, today announced the expansion ... Eastern government. A new centralized high-volume card ... optical memory and the eye-readable data of,this state-of-the-art ...
... deepens customer relationships, WALL, N.J., Aug. 15 ... leader in wireless public safety and,finger-based biometric identification ... quarter ended June 30, 2007. Total revenue ... 30, 2007 decreased 19% to $2.5 million from ...
Cached Biology News:Paracetamol, one of most used analgesics, could slow down bone growth 2LaserCard Corporation Announces Expansion of Middle East Project 2LaserCard Corporation Announces Expansion of Middle East Project 3BIO-key Reports Second Quarter 2007 Results 2BIO-key Reports Second Quarter 2007 Results 3BIO-key Reports Second Quarter 2007 Results 4BIO-key Reports Second Quarter 2007 Results 5